All Stories

BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.

Jun 12, 2025 - 15:00
 0
BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.
Read More

Tags:

Previous Article

What's The Oldest Car You've Ever Driven?

Next Article

RFK Jr. names 8 new members to CDC's vaccine advisory committee after purging en...

Related Posts

Ostro execs talk AI’s transformative role in pharma marketing

Ostro execs talk AI’s transformative role in pharma mar...

Jun 2, 2025  0

FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset

FDA calls for additional manufacturing data in refusal ...

May 27, 2025  0

Endo maps out Men’s Health Month awareness, education drive

Endo maps out Men’s Health Month awareness, education d...

Jun 2, 2025  0